Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.
Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...
Dr. Simon Plyte, Biomunex's CSO, has been invited to present MAIT engagers preclinical data during an oral communication at 2025 SITC Annual meeting -- With a very attractive safety and efficacy ...
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the ...
The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing ...
On November 10, ShillaJen announced that two research findings on 'BAL0891', a first-in-class anticancer drug, were presented at the annual meeting of ...
In 2022, the most-read news about immuno-oncology included an FDA approval for liver cancer, research findings on other potential therapies for liver cancer, a Q&A with a COTA Healthcare executive ...
Nowhere in biopharma does the adage, “Follow the money” better apply, perhaps, than immuno-oncology, whose market size is expected to balloon to $19 billion in 2019 and $34 billion in 2024 (GlobalData ...
Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with ...
If you’re immuno-comprised, you probably know it. So you pay attention when you hear the media bleating about the risks of West Nile and other mosquito-borne viruses that you need to be vigilant about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback